急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL）是儿童最常见的血液恶性肿瘤，近年来儿童 ALL 患者的预后有了显著改善。然而对于复发/难治 ALL 患者，常规的化学治疗缓解率低，预后不佳。随着免疫疗法的兴起，针对 ALL抗原相关的单克隆抗体和嵌合抗原受体T细胞等免疫治疗已被证实对ALL有效，显著改善复发/难治ALL 患者的预后。

Acute lymphoblastic leukemia（ALL）is the most common hematologic malignancy in children. The prognosis of ALL in pediatric patients has significantly improved in recent years. However，for pediatric popu⁃ lation with relapsed/refractory ALL，conventional chemotherapy has a low remission rate and provides no promising prognosis. With the emergence of immunotherapy，immunotherapies targeting ALL antigen ⁃associated monoclonal antibodies and chimeric antigen receptor T cells have shown to be effective against ALL，significantly improving the prognosis in patients with relapsed/refractory ALL. In this article，we review the immunotherapy for ALL in children.